This activation supports T cell proliferation, improves memory features, and when combined with PD‐1 blockade, significantly boosts antitumor immunity and survival, indicating a potent strategy for augmenting cancer immunotherapy.[104] In addition to introducing exogenous substances to modulate mitochondrial function in CD8+ T cells, many novel strategies, such as the use of nanomaterials, temperature regulation, and genetic editing techniques, have also demonstrated promising results in enhancing T cell metabolism and improving immunotherapeutic outcomes. This evidence concerns the gene CD8A and cancer.